Today’s very positive article re: NKTR on S/A:
Nektar Therapeutics (NASDAQ:NKTR) - a bioscience that focuses on the innovation and launch of novel medicines to service cancer, autoimmune disease, and chronic pain - is truly a gift that keeps on giving. Undergoing robust growth, Nektar is powered by various promising fundamental developments.
< snip >
In all, Nektar is brewing an enriched and robust pipeline. The emphasis on combo medicine is a prudent approach toward managing cancers. The recent BMS partnership speaks volume for the substantial prospects in lead molecule NKTR-214 (being studied in 20 different cancer indications). And, we expect most of those franchises to deliver stellar data outcomes and to procure blockbuster sales.
< snip >
https://seekingalpha.com/article/4162776-nektar-therapeutics…
Dan
long NKTR